Sharps Technology Inc (STSS) News

Sharps Technology Enters Into a Five-Year Sales Agreement with Strategic U.S. Medical Products Company Creating +$5O Million in New Revenue for EU Facility

Definitive agreement sells out the 10mL SoloGard production capacity at Sharps’ manufacturing site in the EU...

Form 8-K - Current report

Form 8-K - Current report

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Sharps Technology CEO Urges Shareholders to Vote in Support of the Three Proposals by the July 12 Voting Deadline

Robert Hayes issues a letter to shareholders asking their voting approval on three proposals vital to the...

Sharps Technology Receives Purchase Orders for 1 Million SecureGard Syringes for 2024 Delivery

Swiss-based provider of cosmetic, dental, and ophthalmic injectable therapies issues purchase orders for 1mL...

Sharps Technology Urges Shareholders to Approve the Proposals in connection with the Special Meeting on July 15, 2024

All shareholders of record as of May 17, 2024 are eligible to vote Final votes must be cast by 11:59 p.m...

Sharps Technology Ships First Orders for Securegard Disposable Smart Safety Syringes to Strategic Distribution Partner in Colombia

NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: “STSS” and “STSSW”), an...

Join Sharps Technology’s Exclusive Live Investor Webinar and Q&A Session on June 18

NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: “STSS” and “STSSW”), an...

Sharps Technology Receives $30 Million Purchase Order for Prefillable Copolymer Syringes to be Manufactured at SC Facility

Signed PO secures first 12 months of syringe product orders against Sharps and Nephron’s five-year, $200...

Sharps Technology Secures SC Asset Purchase Exclusivity with $1 Million Escrow Deposit

InjectEZ acquisition establishing Sharps position in the prefillable syringe (PFS) industry in the U.S. has...

Sharps Technology’s SC Asset Purchase and $200 Million Syringe Sales Agreement Paves the Way to Begin Producing Prefillable Specialty Copolymer Syringes in the U.S.

Sharps CEO issues letter to shareholders with details about the InjectEZ acquisition, establishing Sharps...

Sharps Technology Signs 5-Year, $200 Million Syringe Sales Agreement and Amendment to Asset Purchase Agreement to Begin Producing Prefillable Specialty Copolymer Syringes in the U.S.

Sharps will strengthen its manufacturing capacity with a $35 million acquisition of assets, establishing the...

Sharps Technology Positioned to Address Supply Chain Disruptions Resulting from Recent FDA Recalls, Warnings, and Tariffs on Chinese Manufactured Syringes

Sharps CEO issues letter to shareholders on FDA actions and tariffs affecting Chinese syringes. The FDA began...